CY2016010I2 - Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια - Google Patents
Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδιαInfo
- Publication number
- CY2016010I2 CY2016010I2 CY2016010C CY2016010C CY2016010I2 CY 2016010 I2 CY2016010 I2 CY 2016010I2 CY 2016010 C CY2016010 C CY 2016010C CY 2016010 C CY2016010 C CY 2016010C CY 2016010 I2 CY2016010 I2 CY 2016010I2
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| PCT/EP2004/013445 WO2005052004A2 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
| EP04803302A EP1691833B1 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2016010I1 CY2016010I1 (el) | 2016-08-31 |
| CY2016010I2 true CY2016010I2 (el) | 2016-08-31 |
Family
ID=34626385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100465T CY1110689T1 (el) | 2003-11-28 | 2010-05-27 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
| CY2016010C CY2016010I2 (el) | 2003-11-28 | 2016-05-05 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100465T CY1110689T1 (el) | 2003-11-28 | 2010-05-27 | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (el) |
| EP (2) | EP1691833B1 (el) |
| AT (1) | ATE459374T1 (el) |
| AU (1) | AU2004293182B2 (el) |
| BE (1) | BE2016C023I2 (el) |
| CA (1) | CA2544532C (el) |
| CY (2) | CY1110689T1 (el) |
| DE (1) | DE602004025840D1 (el) |
| DK (1) | DK1691833T3 (el) |
| ES (1) | ES2341252T3 (el) |
| FR (1) | FR16C1000I2 (el) |
| HU (1) | HUS1600019I1 (el) |
| LU (1) | LU93067I2 (el) |
| NL (1) | NL300807I2 (el) |
| PL (1) | PL1691833T3 (el) |
| PT (1) | PT1691833E (el) |
| SI (1) | SI1691833T1 (el) |
| WO (1) | WO2005052004A2 (el) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2059536B1 (en) | 2006-08-14 | 2014-01-08 | Xencor, Inc. | Optimized antibodies that target cd19 |
| ES2383710T3 (es) * | 2006-09-08 | 2012-06-25 | Medimmune, Llc | Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes |
| WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| ME02311B (me) | 2010-10-27 | 2016-06-20 | Amgen Res Munich Gmbh | Sredstva za liječenje i postupci liječenja dlbcl |
| CN110038135B (zh) | 2011-03-17 | 2021-03-05 | 伯明翰大学 | 重新定向的免疫治疗 |
| AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| RU2016128726A (ru) | 2013-12-17 | 2018-01-23 | Дженентек, Инк. | Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20 |
| AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
| ES2890079T3 (es) | 2014-05-29 | 2022-01-17 | Macrogenics Inc | Moléculas de unión triespecíficas y métodos de uso de las mismas |
| HRP20201351T1 (hr) | 2014-11-05 | 2020-11-27 | Genentech, Inc. | Postupci proizvodnje dvolančanih proteina u bakteriji |
| RU2705274C2 (ru) | 2014-11-05 | 2019-11-06 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| MX2018005229A (es) | 2015-12-09 | 2019-04-29 | F HoffmannLa Roche Ag | Anticuerpo anti-cd20 de tipo ii y usos del mismo. |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| CA3039430A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| EP3559034B1 (en) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
| AU2018359506A1 (en) | 2017-11-01 | 2020-04-23 | F. Hoffmann-La Roche Ag | Combination therapy with targeted OX40 agonists |
| CN119074915A (zh) | 2018-03-13 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 4-1bb激动剂与抗cd20抗体的治疗剂组合 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| JP7383704B2 (ja) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | 多重特異性結合タンパク質およびその使用方法 |
| CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| EP3877407A1 (en) | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
| EP3962948A1 (en) | 2019-04-30 | 2022-03-09 | Amgen Research (Munich) GmbH | Means and methods of treating burkitt lymphoma or leukemia |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| US12428480B2 (en) | 2019-12-11 | 2025-09-30 | Cullinan Therapeutics, Inc. | Anti-CD19 antibodies and multi-specific binding proteins |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| IL314211A (en) | 2022-03-23 | 2024-09-01 | Genentech Inc | Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3 |
| EP4508081A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024094741A1 (en) | 2022-11-03 | 2024-05-10 | F. Hoffmann-La Roche Ag | Combination therapy with anti-cd19/anti-cd28 bispecific antibody |
| WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2100671C (en) | 1991-02-27 | 1999-02-02 | James S. Huston | Serine rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| ID27512A (id) | 1998-04-21 | 2001-04-12 | Microment Ges Fur Biomedizinis | Polipeptid tetapan cd19xcd3 dan kegunaan-kegunaannya |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| DK1441589T3 (da) * | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer |
-
2004
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en active Application Filing
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I2/el unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2186527A1 (en) | 2010-05-19 |
| FR16C1000I2 (fr) | 2017-02-03 |
| WO2005052004A2 (en) | 2005-06-09 |
| BE2016C023I2 (el) | 2023-12-18 |
| PL1691833T3 (pl) | 2010-08-31 |
| FR16C1000I1 (el) | 2016-06-24 |
| SI1691833T1 (sl) | 2010-06-30 |
| AU2004293182B2 (en) | 2010-02-18 |
| ATE459374T1 (de) | 2010-03-15 |
| CA2544532C (en) | 2015-06-16 |
| DK1691833T3 (da) | 2010-05-03 |
| WO2005052004A3 (en) | 2006-03-09 |
| HUS1600019I1 (hu) | 2016-06-28 |
| LU93067I2 (fr) | 2016-07-11 |
| EP1691833B1 (en) | 2010-03-03 |
| US10000574B2 (en) | 2018-06-19 |
| US20070249529A1 (en) | 2007-10-25 |
| CY2016010I1 (el) | 2016-08-31 |
| DE602004025840D1 (de) | 2010-04-15 |
| AU2004293182A1 (en) | 2005-06-09 |
| CA2544532A1 (en) | 2005-06-09 |
| CY1110689T1 (el) | 2015-06-10 |
| EP1691833A2 (en) | 2006-08-23 |
| ES2341252T3 (es) | 2010-06-17 |
| PT1691833E (pt) | 2010-06-08 |
| NL300807I2 (el) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2016010I2 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
| FR2862654B1 (fr) | Composition amylacee filmogene | |
| DE602004020635D1 (de) | Lanzetten betreffende verbesserungen | |
| DE50310628D1 (de) | Erfahren | |
| DE602004031333D1 (de) | Schalter | |
| DE10393374D2 (de) | Zusammensetzung | |
| EP1559433A4 (en) | STABILIZED COMPOSITION | |
| DE112004001733A5 (de) | Schalter | |
| DK1561472T3 (da) | Faststofsammensætning | |
| DE60320902D1 (de) | Zusammensetzungen mit ausgelöster Freisetzung | |
| EP1689227A4 (en) | HERBICIDAL COMPOSITION | |
| DE502004008876D1 (de) | En schaltglied | |
| DE602004004388D1 (de) | Verdickbare zusammensetzungen | |
| SE0500163L (sv) | Sammansättning | |
| DK1633719T3 (da) | Substituerede spirobenzazepiner | |
| EP1561467A4 (en) | COMPOSITION FOR RECOVERING DAMAGED SKIN | |
| DK1664095T3 (da) | Antimikrobielle polypeptider | |
| BR0310113B1 (pt) | Composições pesticidas | |
| DK1625148T3 (da) | Peptidkompleks | |
| DE50309081D1 (de) | Neue diketopyrrolopyrrolpigmente | |
| ATE365529T1 (de) | Schweisshemmende zusammensetzungen | |
| NO20044140D0 (no) | New Composition | |
| FR2861257B1 (fr) | Composition herbicide | |
| ITMI20040113A1 (it) | Interuttore | |
| NO20053512D0 (no) | IL-8-liknende proteiner |